Table 1 Clinical characteristics of patients with EC

n

161

T stage, n (%)

T1

27 (18.6%)

T2

37 (25.5%)

T3

77 (53.1%)

T4

4 (2.8%)

N stage, n (%)

N0

66 (45.8%)

N1

63 (43.8%)

N2

9 (6.2%)

N3

6 (4.2%)

M stage, n (%)

M0

121 (93.8%)

M1

8 (6.2%)

Pathologic stage, n (%)

Stage I

16 (11.3%)

Stage II

69 (48.6%)

Stage III

49 (34.5%)

Stage IV

8 (5.6%)

Radiation therapy, n (%)

No

107 (74.8%)

Yes

36 (25.2%)

Primary therapy outcome, n (%)

PD

9 (9.7%)

SD

7 (7.5%)

PR

3 (3.2%)

CR

74 (79.6%)

Gender, n (%)

Female

23 (14.3%)

Male

138 (85.7%)

Race, n (%)

Asian

38 (26.6%)

Black or African American

5 (3.5%)

White

100 (69.9%)

Age, n (%)

 ≤ 60

82 (50.9%)

 > 60

79 (49.1%)

Weight, n (%)

 ≤ 70

76 (47.8%)

 > 70

83 (52.2%)

Height, n (%)

 < 170

47 (30.9%)

 ≥ 170

105 (69.1%)

BMI, n (%)

 ≤ 25

84 (55.3%)

 > 25

68 (44.7%)

Histological type, n (%)

Adenocarcinoma

80 (49.7%)

Squamous cell carcinoma

81 (50.3%)

Histologic grade, n (%)

G1

16 (12.7%)

G2

66 (52.4%)

G3

44 (34.9%)

Residual tumor, n (%)

R0

121 (90.3%)

R1

11 (8.2%)

R2

2 (1.5%)

Smoker, n (%)

No

47 (32.9%)

Yes

96 (67.1%)

Alcohol history, n (%)

No

46 (29.1%)

Yes

112 (70.9%)

OS event, n (%)

Alive

97 (60.2%)

Dead

64 (39.8%)

DSS event, n (%)

Alive

115 (71.9%)

Dead

45 (28.1%)

PFI event, n (%)

Alive

83 (51.6%)

Dead

78 (48.4%)

Age, median (IQR)

60 (53, 72)